MENU
+Compare
ARQT
Stock ticker: NASDAQ
AS OF
Jun 30, 04:59 PM (EDT)
Price
$14.03
Change
+$0.29 (+2.11%)
Capitalization
1.64B

ARQT Arcutis Biotherapeutics Forecast, Technical & Fundamental Analysis

Arcutis Biotherapeutics Inc is a medical dermatology company... Show more

ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ARQT with price predictions
Jun 27, 2025

Momentum Indicator for ARQT turns positive, indicating new upward trend

ARQT saw its Momentum Indicator move above the 0 level on June 18, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on June 20, 2025. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ARQT moved below its 50-day moving average on June 27, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.481) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). ARQT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (8.052) is also within normal values, averaging (252.247).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARQT is expected to report earnings to fall 15.95% to -16 cents per share on August 13

Arcutis Biotherapeutics ARQT Stock Earnings Reports
Q2'25
Est.
$-0.17
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.19
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.09
The last earnings report on May 06 showed earnings per share of -20 cents, beating the estimate of -20 cents. With 589.67K shares outstanding, the current market capitalization sits at 1.64B.
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of treatments for dermatological diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3027 Townsgate Road
Phone
+1 805 418-5006
Employees
296
Web
https://www.arcutis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HLEIX92.620.49
+0.53%
JPMorgan Equity Index I
TASHX15.030.04
+0.27%
Transamerica Multi-Asset Income A
STRAX32.890.09
+0.27%
Sterling Capital Behav Lg Cp Val Eq R6
LCGRX24.250.05
+0.21%
Loomis Sayles Small Cap Growth Retail
SUHIX42.24-0.03
-0.07%
DWS Health and Wellness Inst

ARQT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with NRIX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-4.58%
NRIX - ARQT
47%
Loosely correlated
+0.17%
KRYS - ARQT
45%
Loosely correlated
-2.60%
BEAM - ARQT
44%
Loosely correlated
-1.98%
IDYA - ARQT
44%
Loosely correlated
-4.13%
OCUL - ARQT
43%
Loosely correlated
-2.54%
More